Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders

开发 ITI-333,一种 μ-阿片受体部分激动剂和 5HT2A 和 D1 受体拮抗剂,用于治疗阿片类药物使用障碍

基本信息

  • 批准号:
    9841388
  • 负责人:
  • 金额:
    $ 291.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-01-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

RFA-DA-19-002 Principal Investigator/PD: Vanover, Kimberly E. Project Summary/Abstract Intra-Cellular Therapies Inc (ITI), a clinical-stage biopharmaceutical company, is developing ITI-333, a novel compound with high affinity activity at mu opiate (MOP), 5-HT2A, and D1 receptors. The nonclinical profile of ITI-333 suggests a promising medication, lacking abuse liability, with partial agonist activity at MOP receptors useful for treatment of opiate withdrawal in individuals with Opioid Use Disorders (OUD). ITI is currently completing IND-enabling nonclinical safety, toxicology, pharmacokinetic and manufacturing activities, with the goal of launching Phase 1 human clinical evaluation of ITI-333 in healthy volunteers in Q1 2019. ITI seeks to partner with NIDA in the development of this compound for a novel and safe therapeutic for use in treating OUD, requesting support of clinical development of ITI-333, while committing significant internal funds to a parallel program of non-clinical development and CMC activities in support of the clinical plan. To this end, we submit this application, “Development of ITI-333, a µ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders” to NIDA RFA-DA-19-002, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3). Here, we propose a 2-year UG3 program, including a First-in-Man, single ascending dose (SAD) study (ITI-333-001) to assess the safety, tolerability and pharmacokinetics of ITI-333 in healthy volunteers. The safety, tolerability, and pharmacokinetics of multiple, ascending doses (MAD) of ITI-333 will then be evaluated in a single-center in-patient study (ITI-333-002) with the goal of determining a maximally- tolerated dose (MTD). Both studies will be conducted in collaboration with Clinilabs, a NYC-based CRO. In parallel with the MAD study, we will characterize the in vivo receptor pharmacology of ITI-333 at MOP, 5- HT2A, and D1 receptors in human brain using PET imaging (with Dr. Dean Wong, JHU, ITI-333-003), thereby leveraging our SAD data to clinically validate the mechanism of action of ITI-333 and to inform Phase 2 dose selection. These data will enable us to launch a 3-year UH3 program exploring the human abuse liability (HAL) and functional pharmacology of ITI-333 in collaboration with Dr. Sandra Comer (CUMC), a clinical expert in opioid use and abuse. The HAL study (Phase 2a, ITI-333-004) will characterize the opioid receptor antagonist/partial agonist profile of ITI-333 in humans to explore potential abuse liability in humans. Additional Phase 2 studies will evaluate the in vivo functional pharmacology of ITI-333 in a model of withdrawal precipitation in non-treatment seeking heroin users (ITI-333-005) and in a model of mu-opioid receptor blockade in treatment-seeking heroin users (ITI-333-006). Together, we believe this clinical development plan with inform further development of ITI-333 and the selection of a cogent Phase 3 clinical path toward FDA approval as a medication for the treatment of OUD.
首席调查员/PD:Vanover,Kimberly E. 项目摘要/摘要 临床阶段生物制药公司细胞内疗法公司(ITI)正在开发一种新型的ITI-333 对Mu阿片(MOP)、5-HT2A和D1受体具有高亲和力的化合物。非临床型心绞痛 ITI-333建议一种前景看好的药物,缺乏滥用倾向,在MOP具有部分激动剂活性 受体可用于治疗阿片类药物使用障碍(OUD)患者的阿片类药物戒断。ITI是 目前正在完成启用IND的非临床安全性、毒理学、药代动力学和制造 活动,目标是在第一季度在健康志愿者中启动ITI-333的第一阶段人类临床评估 2019年。ITI寻求与NIDA合作开发这种化合物,以开发一种新的安全治疗方法 用于治疗OUD,请求支持ITI-333的临床开发,同时承诺 内部资金用于非临床开发和CMC活动的并行计划,以支持临床 计划。为此,我们提交了这项申请,名为ITI-333,一种微阿片受体部分 激动剂和5HT2A和D1受体拮抗剂治疗阿片类药物使用障碍 RFA-DA-19-002,预防和治疗阿片类药物使用障碍和过量用药的发展 (UG3/UH3)。在这里,我们建议一个为期2年的UG3计划,包括第一个人,单次递增剂量 (SAD)研究(ITI-333-001)评估ITI-333在健康人群中的安全性、耐受性和药代动力学 志愿者。ITI-333多次递增剂量(MAD)的安全性、耐受性和药物动力学 然后在单中心住院研究(ITI-333-002)中进行评估,目标是确定最大- 耐受剂量(MTD)。这两项研究都将与总部位于纽约的CRO Clinilabs合作进行。在……里面 在MAD研究的同时,我们将表征ITI-333在MOP,5-MAP的体内受体药理。 人脑中的HT2a和D1受体的PET成像(与Dean Wong,JHU,ITI-333-003),从而 利用我们的SAD数据在临床上验证ITI-333的作用机制,并向第二阶段提供信息 剂量选择。这些数据将使我们能够启动一个为期3年的UH3计划,探索人类虐待 ITI-333的责任(HAL)和功能药理学与桑德拉·科默博士(CUMC)合作,a 阿片类药物使用和滥用方面的临床专家。HAL研究(2a阶段,ITI-333-004)将描述阿片类药物的特征 ITI-333在人类中的受体拮抗剂/部分激动剂图谱,以探索人类潜在的滥用倾向。 其他第二阶段研究将在一个模型中评估ITI-333的体内功能药理学 非寻求治疗海洛因使用者的戒断沉淀(ITI-333-005)和单位阿片类药物模型 寻求治疗的海洛因依赖者的受体阻断(ITI-333-006)。总而言之,我们相信这个临床 开发计划,告知ITI-333的进一步开发和选择令人信服的3期临床 通向FDA批准作为治疗OUD的药物的道路。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SANDRA D COMER其他文献

SANDRA D COMER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SANDRA D COMER', 18)}}的其他基金

Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose
经皮膈神经刺激治疗阿片类药物过量
  • 批准号:
    10681111
  • 财政年份:
    2023
  • 资助金额:
    $ 291.71万
  • 项目类别:
Phase 1 and 2 studies of sublingual dexmedetomidine, an alpha 2 adrenergic agonist, for treating opioid withdrawal
舌下含服右美托咪定(一种 α2 肾上腺素能激动剂)用于治疗阿片类药物戒断的 1 期和 2 期研究
  • 批准号:
    10478324
  • 财政年份:
    2022
  • 资助金额:
    $ 291.71万
  • 项目类别:
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials
开发逆转芬太尼及其类似物过量的单克隆抗体:从制造到临床试验
  • 批准号:
    10615519
  • 财政年份:
    2022
  • 资助金额:
    $ 291.71万
  • 项目类别:
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components
多价阿片类疫苗成分的 1a/1b 期临床试验
  • 批准号:
    10782616
  • 财政年份:
    2018
  • 资助金额:
    $ 291.71万
  • 项目类别:
CERC-501 Kappa Antagonist for Nicotine Dependence
CERC-501 尼古丁依赖性 Kappa 拮抗剂
  • 批准号:
    9041849
  • 财政年份:
    2016
  • 资助金额:
    $ 291.71万
  • 项目类别:
Dynamic Contrast-Enhanced MRI to Measure Blood-Brain Barrier Permeability in Substance Abusers
动态对比增强 MRI 测量药物滥用者的血脑屏障渗透性
  • 批准号:
    9066619
  • 财政年份:
    2015
  • 资助金额:
    $ 291.71万
  • 项目类别:
Dynamic Contrast-Enhanced MRI to Measure Blood-Brain Barrier Permeability in Substance Abusers
动态对比增强 MRI 测量药物滥用者的血脑屏障渗透性
  • 批准号:
    8989439
  • 财政年份:
    2015
  • 资助金额:
    $ 291.71万
  • 项目类别:
Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users
过量教育和向海洛因使用者开纳洛酮处方的风险和益处
  • 批准号:
    8694865
  • 财政年份:
    2014
  • 资助金额:
    $ 291.71万
  • 项目类别:
Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users
过量教育和向海洛因使用者开纳洛酮处方的风险和益处
  • 批准号:
    9330829
  • 财政年份:
    2014
  • 资助金额:
    $ 291.71万
  • 项目类别:
Laboratory Model for Heroin Abuse Medications
海洛因滥用药物的实验室模型
  • 批准号:
    7628363
  • 财政年份:
    2008
  • 资助金额:
    $ 291.71万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 291.71万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 291.71万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 291.71万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 291.71万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 291.71万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 291.71万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 291.71万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 291.71万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 291.71万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 291.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了